◒
Tricyclic Antidepressants: Difference between revisions
From WikiMSK
(Created page with "{{Partial}} Tricyclic Antidepressants (TCAs) are well-studied and widely recommended as a first-line therapy for neuropathic pain treatment. They have proven effective in managing peripheral neuropathy, post-herpetic neuralgia, and neuropathic pain following spinal cord injury, but exhibit limited efficacy for radiculopathy, HIV, and chemotherapy-induced peripheral neuropathy. The primary pain-relieving mechanism of TCAs is the inhibition of serotonin and norepinephrine...") Ā |
No edit summary |
||
| Line 1: | Line 1: | ||
{{Partial}} | {{Partial}} | ||
Tricyclic Antidepressants (TCAs) are well-studied and widely recommended as a first-line therapy for neuropathic pain | Tricyclic Antidepressants (TCAs) are well-studied and widely recommended as a first-line therapy for [[Neuropathic Pain|neuropathic pain]]. They have proven effective in managing peripheral neuropathy, post-herpetic neuralgia, and neuropathic pain following spinal cord injury, but exhibit limited efficacy for [[Radicular Pain and Radiculopathy|radiculopathy]], HIV, and chemotherapy-induced peripheral neuropathy. The primary pain-relieving mechanism of TCAs is the inhibition of serotonin and norepinephrine reuptake, although they also block [[histamine]], adrenaline, acetylcholine, and [[Sodium Channelopathies|sodium channels]], which contributes to their broad side effect profile. Notably, their analgesic effect is independent of their antidepressant effect and occurs at a lower dosage (20-30% of the antidepressant dosage).<ref>{{Cite journal|last=Mu|first=Alex|last2=Weinberg|first2=Erica|last3=Moulin|first3=Dwight E.|last4=Clarke|first4=Hance|date=2017-11|title=Pharmacologic management of chronic neuropathic pain: Review of the Canadian Pain Society consensus statement|url=https://pubmed.ncbi.nlm.nih.gov/29138154|journal=Canadian Family Physician Medecin De Famille Canadien|volume=63|issue=11|pages=844ā852|issn=1715-5258|pmc=5685445|pmid=29138154}}</ref> | ||
A Cochrane review of 61 randomized controlled trials found that TCAs had a number needed to treat (NNT) of 3.6 to achieve moderate pain relief, with a number needed to harm (NNH) of 28 for major adverse effects and 9 for minor adverse effects.<ref>{{Cite journal|last=Saarto|first=T.|last2=Wiffen|first2=P. J.|date=2007-10-17|title=Antidepressants for neuropathic pain|url=https://pubmed.ncbi.nlm.nih.gov/17943857|journal=The Cochrane Database of Systematic Reviews|issue=4|pages=CD005454|doi=10.1002/14651858.CD005454.pub2|issn=1469-493X|pmid=17943857}}</ref> A separate trial determined that high-dose TCAs had an NNT of 7.6 and an NNH of 9.2 in neuropathic pain associated with spinal cord injury.<ref>{{Cite journal|last=Sindrup|first=SĆøren H.|last2=Otto|first2=Marit|last3=Finnerup|first3=Nanna B.|last4=Jensen|first4=Troels S.|date=2005-06|title=Antidepressants in the treatment of neuropathic pain|url=https://pubmed.ncbi.nlm.nih.gov/15910402|journal=Basic & Clinical Pharmacology & Toxicology|volume=96|issue=6|pages=399ā409|doi=10.1111/j.1742-7843.2005.pto_96696601.x|issn=1742-7835|pmid=15910402}}</ref> It is recommended to trial TCAs for four to eight weeks; inadequate pain relief should prompt consideration of alternative first-line medications or combination therapy.<ref>{{Cite journal|last=Dworkin|first=Robert H.|last2=O'Connor|first2=Alec B.|last3=Audette|first3=Joseph|last4=Baron|first4=Ralf|last5=Gourlay|first5=Geoffrey K.|last6=HaanpƤƤ|first6=Maija L.|last7=Kent|first7=Joel L.|last8=Krane|first8=Elliot J.|last9=Lebel|first9=Alyssa A.|last10=Levy|first10=Robert M.|last11=Mackey|first11=Sean C.|date=2010-03|title=Recommendations for the pharmacological management of neuropathic pain: an overview and literature update|url=https://pubmed.ncbi.nlm.nih.gov/20194146|journal=Mayo Clinic Proceedings|volume=85|issue=3 Suppl|pages=S3ā14|doi=10.4065/mcp.2009.0649|issn=1942-5546|pmc=2844007|pmid=20194146}}</ref><ref>{{Cite journal|last=Bates|first=Daniel|last2=Schultheis|first2=B. Carsten|last3=Hanes|first3=Michael C.|last4=Jolly|first4=Suneil M.|last5=Chakravarthy|first5=Krishnan V.|last6=Deer|first6=Timothy R.|last7=Levy|first7=Robert M.|last8=Hunter|first8=Corey W.|date=2019-06-01|title=A Comprehensive Algorithm for Management of Neuropathic Pain|url=https://pubmed.ncbi.nlm.nih.gov/31152178|journal=Pain Medicine (Malden, Mass.)|volume=20|issue=Suppl 1|pages=S2āS12|doi=10.1093/pm/pnz075|issn=1526-4637|pmc=6544553|pmid=31152178}}</ref> Caution is advised when prescribing TCAs to elderly and frail patients due to potential adverse effects, such as falls, cardiac arrhythmias, orthostasis, urinary retention, and dry mouth. | A Cochrane review of 61 randomized controlled trials found that TCAs had a number needed to treat (NNT) of 3.6 to achieve moderate pain relief, with a number needed to harm (NNH) of 28 for major adverse effects and 9 for minor adverse effects.<ref>{{Cite journal|last=Saarto|first=T.|last2=Wiffen|first2=P. J.|date=2007-10-17|title=Antidepressants for neuropathic pain|url=https://pubmed.ncbi.nlm.nih.gov/17943857|journal=The Cochrane Database of Systematic Reviews|issue=4|pages=CD005454|doi=10.1002/14651858.CD005454.pub2|issn=1469-493X|pmid=17943857}}</ref> A separate trial determined that high-dose TCAs had an NNT of 7.6 and an NNH of 9.2 in neuropathic pain associated with spinal cord injury.<ref>{{Cite journal|last=Sindrup|first=SĆøren H.|last2=Otto|first2=Marit|last3=Finnerup|first3=Nanna B.|last4=Jensen|first4=Troels S.|date=2005-06|title=Antidepressants in the treatment of neuropathic pain|url=https://pubmed.ncbi.nlm.nih.gov/15910402|journal=Basic & Clinical Pharmacology & Toxicology|volume=96|issue=6|pages=399ā409|doi=10.1111/j.1742-7843.2005.pto_96696601.x|issn=1742-7835|pmid=15910402}}</ref> It is recommended to trial TCAs for four to eight weeks; inadequate pain relief should prompt consideration of alternative first-line medications or combination therapy.<ref>{{Cite journal|last=Dworkin|first=Robert H.|last2=O'Connor|first2=Alec B.|last3=Audette|first3=Joseph|last4=Baron|first4=Ralf|last5=Gourlay|first5=Geoffrey K.|last6=HaanpƤƤ|first6=Maija L.|last7=Kent|first7=Joel L.|last8=Krane|first8=Elliot J.|last9=Lebel|first9=Alyssa A.|last10=Levy|first10=Robert M.|last11=Mackey|first11=Sean C.|date=2010-03|title=Recommendations for the pharmacological management of neuropathic pain: an overview and literature update|url=https://pubmed.ncbi.nlm.nih.gov/20194146|journal=Mayo Clinic Proceedings|volume=85|issue=3 Suppl|pages=S3ā14|doi=10.4065/mcp.2009.0649|issn=1942-5546|pmc=2844007|pmid=20194146}}</ref><ref>{{Cite journal|last=Bates|first=Daniel|last2=Schultheis|first2=B. Carsten|last3=Hanes|first3=Michael C.|last4=Jolly|first4=Suneil M.|last5=Chakravarthy|first5=Krishnan V.|last6=Deer|first6=Timothy R.|last7=Levy|first7=Robert M.|last8=Hunter|first8=Corey W.|date=2019-06-01|title=A Comprehensive Algorithm for Management of Neuropathic Pain|url=https://pubmed.ncbi.nlm.nih.gov/31152178|journal=Pain Medicine (Malden, Mass.)|volume=20|issue=Suppl 1|pages=S2āS12|doi=10.1093/pm/pnz075|issn=1526-4637|pmc=6544553|pmid=31152178}}</ref> Ā | ||
Ā | |||
== Prescribing == | |||
For nortriptyline and amitriptyline, start at 10ā25 mg at dinner time. The maximum daily dose is 150mg. | |||
Ā | |||
Caution is advised when prescribing TCAs to elderly and frail patients due to potential adverse effects, such as falls, cardiac arrhythmias, orthostasis, urinary retention, and dry mouth. Also further caution with autonomic neuropathy, urinary retension, glaucoma, or if also taking an SNRI, SSRI, MAOI, and/or tramadol. | |||
==References== | ==References== | ||
<references/> | <references/> | ||
{{Reliable sources}} | {{Reliable sources}} | ||
[[Category:Pharmacology]] | |||
Revision as of 08:58, 30 March 2023
This article is still missing information.
Tricyclic Antidepressants (TCAs) are well-studied and widely recommended as a first-line therapy for neuropathic pain. They have proven effective in managing peripheral neuropathy, post-herpetic neuralgia, and neuropathic pain following spinal cord injury, but exhibit limited efficacy for radiculopathy, HIV, and chemotherapy-induced peripheral neuropathy. The primary pain-relieving mechanism of TCAs is the inhibition of serotonin and norepinephrine reuptake, although they also block histamine, adrenaline, acetylcholine, and sodium channels, which contributes to their broad side effect profile. Notably, their analgesic effect is independent of their antidepressant effect and occurs at a lower dosage (20-30% of the antidepressant dosage).[1]
A Cochrane review of 61 randomized controlled trials found that TCAs had a number needed to treat (NNT) of 3.6 to achieve moderate pain relief, with a number needed to harm (NNH) of 28 for major adverse effects and 9 for minor adverse effects.[2] A separate trial determined that high-dose TCAs had an NNT of 7.6 and an NNH of 9.2 in neuropathic pain associated with spinal cord injury.[3] It is recommended to trial TCAs for four to eight weeks; inadequate pain relief should prompt consideration of alternative first-line medications or combination therapy.[4][5]
Prescribing
For nortriptyline and amitriptyline, start at 10ā25 mg at dinner time. The maximum daily dose is 150mg.
Caution is advised when prescribing TCAs to elderly and frail patients due to potential adverse effects, such as falls, cardiac arrhythmias, orthostasis, urinary retention, and dry mouth. Also further caution with autonomic neuropathy, urinary retension, glaucoma, or if also taking an SNRI, SSRI, MAOI, and/or tramadol.
References
- ā Mu, Alex; Weinberg, Erica; Moulin, Dwight E.; Clarke, Hance (2017-11). "Pharmacologic management of chronic neuropathic pain: Review of the Canadian Pain Society consensus statement". Canadian Family Physician Medecin De Famille Canadien. 63 (11): 844ā852. ISSN 1715-5258. PMC 5685445. PMID 29138154. Check date values in:
|date=(help) - ā Saarto, T.; Wiffen, P. J. (2007-10-17). "Antidepressants for neuropathic pain". The Cochrane Database of Systematic Reviews (4): CD005454. doi:10.1002/14651858.CD005454.pub2. ISSN 1469-493X. PMID 17943857.
- ā Sindrup, SĆøren H.; Otto, Marit; Finnerup, Nanna B.; Jensen, Troels S. (2005-06). "Antidepressants in the treatment of neuropathic pain". Basic & Clinical Pharmacology & Toxicology. 96 (6): 399ā409. doi:10.1111/j.1742-7843.2005.pto_96696601.x. ISSN 1742-7835. PMID 15910402. Check date values in:
|date=(help) - ā Dworkin, Robert H.; O'Connor, Alec B.; Audette, Joseph; Baron, Ralf; Gourlay, Geoffrey K.; HaanpƤƤ, Maija L.; Kent, Joel L.; Krane, Elliot J.; Lebel, Alyssa A.; Levy, Robert M.; Mackey, Sean C. (2010-03). "Recommendations for the pharmacological management of neuropathic pain: an overview and literature update". Mayo Clinic Proceedings. 85 (3 Suppl): S3ā14. doi:10.4065/mcp.2009.0649. ISSN 1942-5546. PMC 2844007. PMID 20194146. Check date values in:
|date=(help) - ā Bates, Daniel; Schultheis, B. Carsten; Hanes, Michael C.; Jolly, Suneil M.; Chakravarthy, Krishnan V.; Deer, Timothy R.; Levy, Robert M.; Hunter, Corey W. (2019-06-01). "A Comprehensive Algorithm for Management of Neuropathic Pain". Pain Medicine (Malden, Mass.). 20 (Suppl 1): S2āS12. doi:10.1093/pm/pnz075. ISSN 1526-4637. PMC 6544553. PMID 31152178.
Literature Review
Literature Review
- Reviews from the last 7 years: review articles, free review articles, systematic reviews, meta-analyses, NCBI Bookshelf
- Articles from all years: PubMed search, Google Scholar search.
- TRIP Database: clinical publications about evidence-based medicine.
- Other Wikis: Radiopaedia, Wikipedia Search, Wikipedia I Feel Lucky, Orthobullets,
